Diffused suberitrodermic psoriasis induced by infliximab;Psoriasi suberitrodermica diffusa indotta da infliximab

Reumatismo

Volumn 59, Issue 4, 2007, Pages 328-331

  Bruzzese, Vincenzo ^a,b  

^a UOC di Medicina Interna   (Italy)

^b NONE   (Italy)

Author keywords

INF alpha; Infliximab; Paradoxical effect; Psoriasis; TNF alpha

Indexed keywords

CORTISONE; INFLIXIMAB; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; FOOT; HAND; HUMAN; LIMB; MALE; PATHOGENESIS; PSORIASIS; TRUNK; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; DRUG ERUPTION; IMMUNOLOGY; SKIN; SPONDYLARTHRITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; CYCLOSPORINE; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; SKIN; SPONDYLARTHRITIS; TREATMENT OUTCOME;

EID: 55449108368     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and mangement. Am J Clin.Dermtol 2000; 1: 159-65.
2. Wolfe JT, Singh A, Lessin SR, Jarworsky C, Rook A H. De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma. J Am Acad Dermatol 1995; 32: 887-93.
3. Taylor C, Burns DA, Wiselka M J. Estensive psoraisis induced by interferon for chronic hepatitis C. Postgrad Med J 2000; 76: 365-7.
4. Adams DR, Bucket T, Sceppa JA. Infliximab associated new onset psoriasis. Drugs Dermatol 2006; 5: 178-9.
5. Thielen AM, Kuenzli S, Saurat JH. Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005; 211: 209-17.
6. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by Infliximab. J Drugs Dermatol 2004; 3: 439-40.
7. Cohen JD, Bournerias I, Buffard V, Pauffler A, Chevalier X, Bagot M, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007; 34: 380-5.
8. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by Anti-Tumor Necrosis Factor Therapy. A Paradoxical Adverse Reaction. Arthritis Rheum 2005; 52: 2513-8.
9. Kary S, Worm M., Audring H, Husher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumor necrosis factor alfa antagonists. Ann Rheum Dis 2006; 65: 405-7.
10. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by Infliximab Ann Pharmacother 2004; 38: 54-7.
11. Ritchlin C, Tausk F. A medical conundrum:onset of psoriasis in patients receiving antitumor necrosis factor agents Ann Rheum Dis 2006; 65: 1541-4.
12. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alfa inhibitors. Rheumatology 2005; 44: 172-5.
13. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytochine-induced dendritic cell activation. Immunity 2004; 20: 539-50.
14. de Gannes GC, Ghoreichi M, Pope J, Russel A, Adam S, Shojania K, et al. Psoriasis and pustular dermatitis triggered by TNF-alfa Inhibitors in patients with rheumatologic conditions Arch Dermatol 2007; 143: 223-31.
15. Bennet L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in sistemic lupus erythematous blood. J Exp Med 2003; 197: 711-23.
16. Nestle FO, Conrad C, Tun-Kyi A, Homey B, gombert M, Boyman O, et al. Plasmocytoid predendritic cells initiate psoriasis through interferon-alfa production. J Exp Med 2005; 202: 135-43.